/
EYPT
$13.48-$0.05 (-0.37%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.2B
86M shares
52-week range
$9.65 – $19.11
40% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Change+$3.49
EyePoint, Inc. Common Stock
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
www.eyepoint.bio- Employees
- 214
- IPO / List date
- Jan 27, 2005
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds EYPT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 117,300 | $1.5M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-12-09 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded EYPT yet.
